Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 October 2025 | Story Lacea Loader

The University of the Free State (UFS) Executive Committee (Exco), Institutional Representative Council (ISRC), and Campus Student Representative Councils (CSRCs) of the three campuses met on 15 October 2025 and reached an agreement regarding the implementation of the phasing out of provisional registration. 
The discussions were held in light of the decision made by the UFS Council on 26 September 2025 to phase out the provisional registration – a decision that led to the recent protest actions on the three campuses the past week. 

In a spirit of working towards a fairer, more equitable, and sustainable financial support system for all academically deserving students, Exco and the student leadership agreed that provisional registration will be phased out over a period of two years (2026-2027). This phased approach allows the university time to assess the risks students are facing with a view to assisting students. This means that from 1 January 2026, all students will be on a fully registered system. 

In recognition of the challenges students face, the outcomes of the meeting reflect the university’s ongoing commitment, and it ensures that all students are supported within a financially sustainable framework. It also reaffirms the university’s commitment to expanding access through enhanced financial support while sustaining the UFS as a national asset for future generations. 

The Exco remains committed to ongoing engagement with student leadership through open dialogue that reflects the university’s values, appreciates the constructive approach taken by the student leadership, and remains dedicated to working collaboratively in the best interest of all students and the broader university community.

News Archive

UFS to monitor the use of ARV-drugs on pregnant women and children
2004-12-08

The University of the Free State (UFS) is to establish a Pharmacovigilance Centre that will monitor the effects of Anti-Retroviral (ARV) drugs on HIV positive pregnant women and children starting early in the new year.

The UFS is one of only two institutions chosen by the Minister of Health, Dr Manto Tshabalala-Msimang, to establish such an ARV monitoring centre.

The other centre will be based at Medical University of South Africa (MEDUNSA) and will concentrate mainly on monitoring the effects of the drugs on adults.

“The establishment of the UFS’s Pharmaconvigilance Centre forms part of government’s Comprehensive Plan on HIV and AIDS, often termed the roll-out plan for ARV drugs. The centre’s primary responsibility will be to specifically monitor the use of these drugs in pregnant women, and children under the age of 13,” said Prof Andrew Walubo of the UFS’s Department of Pharmacology.

“Although most of the side effects of ARV drugs have been identified in other countries, it has now become critical to identify the side effects amongst the South African population. This is important because many people will be exposed to the drugs within a short time. Our aim is so identify the most common side effects and make recommendations for the prevention thereof. The centre will help in detecting the risk of using anti-retroviral drugs in pregnancy and children, and prevention of adverse drug reactions,” said Prof Walubo.

According to Prof Walubo 12 drugs will be monitored – these drugs will be selected according to the patient’s profile.

The centre will comprise of two components: A pregnancy registry, which will focus on a new-born child up until two months and a pediatric registry, which will focus on children who are born of mothers who used ARV drugs and children using ARV drugs.

According to Prof Walubo, the Pharmaconvigilance Centre will also be responsible for offering relevant technical advice, training and selected research on ARV drugs in these patients.

The centre will be fully sponsored by the national Department of Health. It will be based in the UFS’s Faculty of Health Sciences, Department of Pharmacology, and will be run in collaboration with experts from different departments in the faculty.

Media release
Issued by: Lacea Loader
Media Representative
Tel: (051) 401-2584
Cell: 083 645 2454
E-mail: loaderl.stg@mail.uovs.ac.za
8 December 2004

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept